• In years of experience with virtual meetings, Within3 has determined four critical practices that can have an enormous impact on your virtual program’s overall results. These best practices can be used to optimize your first virtual advisory board, speaker deck review, online steering committee, and more.

    Read More

  • As the market leader conducting hundreds of online virtual advisory board meetings each year around the globe, Within3 shares five key best practices in advisor engagement. Best practices in participant selection, expectation setting, honoraria, contracting, and engagement are discussed within this whitepaper.

    Read More

  • Recently more companies have been turning to online discussion platforms to strengthen their market insights, reduce cost, and reduce time to market. This paper covers common ROI results cited by Within3 clients who have used the virtual platform to gain critical information for their businesses.

    Read More

  • While social media staples such as Twitter, Facebook, LinkedIn, and others have become standard marketing procedure for most pharmaceutical companies, a new trend has emerged over the past several years – using custom social media-like platforms to solve the critical, more specific communications challenges that are commonplace throughout the drug lifecycle. Called “online discussion platforms”, these solutions take the best features of social media communication, augment them with heavy compliance safeguards, and tailor them for specific use by life sciences professionals and their extended healthcare stakeholders. Discover how these platforms are being used to engage large groups.

    Read More

  • When optimally managed, the relationship between pharmaceutical organizations and healthcare professionals (HCPs) on the frontlines of patient care is bi-directional. A leading pharmaceutical organization’s joint medical affairs and commercial team, purposed with gaining insight and treatment perspectives about prescribing preferences and informational needs, was tasked with identifying an innovative approach to facilitating bi-directional discussions with leading clinicians around the country. This case study explains how they did it.

    Read More

  • Based on an analysis of hundreds of Within3 programs from around the world, this Whitepaper will outline the current trends of how companies are choosing to engage with small teams of payers, patients, physicians, caregivers, and more.

    Read More

  • The Physician Payment Sunshine Act is an initiative that requires manufacturers of drugs, medical devices and biologicals to report all payments and “transfers of value” given to US physicians and teaching hospitals. The program is intended to provide greater clarity into the relationships between pharmaceutical and device companies and healthcare providers.

    Read More

  • It seems as if all things are online now – shopping, education, entertainment – it was only a matter of time before the life sciences industry followed suit. Life science companies are constantly tasked with engaging healthcare professionals in order to help with all aspects of a drug lifecycle. The advent of online discussion platforms has allowed companies to engage with these stakeholders more frequently and at lower costs.

    Read More

  • Modern technology has the ability to improve speakers bureau programs. At a high level, speakers bureau software can reduce costs and expertly organize and schedule dinner meetings, creating a strong foundation for effective and valuable programs. However, the challenges with existing programs has not allowed for the highest quality materials to be presented by the best educated speakers to the most extensive audiences.

    The following white paper identifies three crucial communication challenges within a speakers bureau program and how to address them.

    Read More

  • The 505(b)(2) regulatory pathway is one of three categories of new drug applications (NDA). While the application requires full safety and effectiveness reports, it gives the FDA permission to use data not gathered by the NDA applicant, avoiding unnecessary duplicate analyses. Employing a 505(b)(2) regulatory strategy can offer significant benefits, encouraging innovation while offering a faster, more cost-efficient way to drug development.

    Read More

  • The Institute of Medicine (IOM) defines patient-centered care as, “Providing care that is respectful of and responsive to individual patient preferences, needs and values, and ensuring that patient values guide all clinical decisions.” Practicing patient-centered care improves patient outcomes while cultivating the quality of doctor-patient relationships. How can this translate to the marketing of pharmaceuticals?

    Read More

  • 2015 was a wild ride for the pharma industry. We saw high profile mergers, landmark developments and, yes, damaging criticisms. These events, for better or for worse, are likely to shape the pharma landscape for 2016. Here are the top stories that consistently found their way into the headlines.

    Read More

  • Finding innovative ways to engage with stakeholders is a tricky business in the pharma industry. With strict industry regulations and vague guidance, it’s difficult to know what pharma companies can and cannot do on social media. However, social media is an important and strategic way to gather stakeholder insight and should be considered in pharmaceutical companies’ business plans. The following article highlights 10 best practices for opening dialogue with HCPs using social media.

    Read More

  • This past spring, the U.S. Food and Drug Administration approved the first biosimilar product in the U.S. Biosimilars are not new to the industry; they have been on the market in Europe since 2006. But, this newer practice has pharma watching closely as it could determine innovative, lower cost go-to-market therapies.

    The following article describes the argument, fallout and possible solutions for the introduction of biosimilars as therapeutic substitutions.

    Read More

  • The pharmaceutical industry has been at the center of controversy for some time now. Like everything in the pharmaceutical industry, there are complexities in the business, including drug pricing. This article illustrates how Within3 provides pharmaceutical companies a way to collaborate with stakeholders to respond quickly to the marketplace while being responsive to the unique needs of the industry.

    Read More

  • As pharmaceutical manufacturers are challenged with increasing operational efficiencies, reducing costs, and delivering more value, they are motivated to find new ways to address business objectives. Learn how to introduce a digital collaboration solution into your organization.

    Read More

  • Not all moderators are created equal. Valuable moderators must be closely involved in the planning process and have an in-depth understanding of the client needs.

    In the following checklist, we provide some useful guidelines to look for when reviewing your next advisory board moderator.

    Read More

  • As medical and brand directors become more knowledgeable about digital collaboration, we are seeing a shift in the industry. Learn how to bring more innovative healthcare engagement solutions to your strategic planning.

    Read More

  • Now a reality, the Physician Payment Sunshine Act (PPSA) has life sciences companies grappling with new systems for tracking, compiling and reporting physician payments for regulatory disclosure. Discover new communication strategies to help engage HCPs while addressing privacy concerns.

    Read More